Anika Therapeutics reported $24.86M in Gross Profit on Sales for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Gross Profit On Sales Change
Abbott ABT:US USD 5.5B 283M
Agenus AGEN:US USD 22.46M 3.56M
Agios Pharmaceuticals AGIO:US USD 3M 2.15M
Clovis Oncology CLVS:US USD 22.06M 873K
Halozyme Therapeutics HALO:US USD 161.66M 43.24M
Insmed INSM:US USD 54.26M 5.43M
Integra Lifesciences IART:US USD 240.94M 13.6M
Intrexon XON:US USD 15.14M 14.04M
Johnson & Johnson JNJ:US USD 15.94B 56M
Karyopharm Therapeutics KPTI:US USD 35.16M 3.58M
MacroGenics MGNX:US USD 38.59M 14.99M
Merit Medical Systems MMSI:US USD 128.57M 6.49M
Peregrine Pharmaceuticals PPHM:US USD 4.15M 4.97M
Smith & Nephew PLC SN/:LN 1.83B 49M
Stryker SYK:US USD 3.26B 461M
Veracyte VCYT:US USD 49.58M 1.75M
Zimmer Biomet Holdings Inc ZBH:US USD 1.3B 123.2M